Delhi Pharma Company to Get IP for Alzheimer’s disease (AS) |
News and Updates
eMediNexus Coverage from: 
Delhi Pharma Company to Get IP for Alzheimer’s disease (AS)
Chethan Kumar,  13 May 2022
Coronavirus Live Count Map India

remove_red_eye 536 Views
COVID-19 Vaccine Updates


#Multispeciality

1 Read Comments                

Scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) developed a drug molecule for Alzheimer’s treatment more than a year ago. A Delhi-based pharma, Hamsa Biopharma has obtained the intellectual property rights of the path-breaking drug molecule. The company will design and implement drug post-marketing trials along with its parent company in the US, IGC pharma.The drug molecule, TGR63 works on the pathways that render neurons i.e., brain cells dysfunctional ...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now